GlobeNewswire Inc.··Mink TherapeuticsMiNK Therapeutics Shows Promise in Gastric Cancer With 77% Disease Control Rate
MiNK Therapeutics reported Phase II data for agenT-797 combination therapy in PD-1 refractory gastroesophageal cancer, achieving 77% disease control with improved survival metrics.
INKTPhase II trialiNKT cell therapy